Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP006: Long term maintenance treatment with vedolizumab in pediatric IBD: a three-year follow-up of the prospective multicenter VEDOKIDS studyECCO'25 Berlin
Year: 2025
Authors: Turner, Dan
DOP007: Change in Histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trialECCO'25 Berlin
Year: 2025
Authors: Jairath, Vipul
DOP008: High clinical and endoscopic remission rate with Vedolizumab in early CD patients: the 2nd interim analysis from a prospective multicenter interventional Study (EARLY CD)ECCO'25 Berlin
Year: 2025
Authors: Liu, Jing
DOP009: Effectiveness and Safety of Advanced Combination Treatment (ACT) in patients with refractory inflammatory bowel disease or concomitant immune mediated disease or extra-intestinal manifestations: A Multi-Center Canadian StudyECCO'25 Berlin
Year: 2025
Authors: Solitano, Virginia
DOP010: Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics studyECCO'25 Berlin
Year: 2025
Authors: Dreesen, Erwin
DOP011: Colectomy rates of newly diagnosed Finnish Ulcerative Colitis patients are decreasingECCO'25 Berlin
Year: 2025
Authors: Kontola, Kristi
DOP012: Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical studyECCO'25 Berlin
Year: 2025
Authors: Schreieck, Amelie
DOP013: Risk of immune mediated inflammatory diseases associated with anti-TNFs and ustekinumab in Crohn’s disease: a nationwide population-based cohort studyECCO'25 Berlin
Year: 2025
Authors: Kirchgesner, Julien
DOP014: Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension studyECCO'25 Berlin
Year: 2025
Authors: Atreya, Raja
DOP015: Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s Program.ECCO'25 Berlin
Year: 2025
Authors: Connor, Susan Jane
DOP016: Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term ExtensionECCO'25 Berlin
Year: 2025
Authors: Ferrante, Marc
DOP017: Infliximab induction fails to reach targets in Perianal Fistulizing Crohn’s Disease: first results from the ATLANTIC studyECCO'25 Berlin
Year: 2025
Authors: Mulders, Lieven
DOP018: Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programmeECCO'25 Berlin
Year: 2025
Authors: Vermeire, Séverine
DOP019: Reduced Gut Microbial Amino Acid Auxotrophies and Enhanced Tryptophan Degradation in Inflammatory Bowel DiseaseECCO'25 Berlin
Year: 2025
Authors: Waschina, Silvio
DOP020: Baseline Microbiota and Differences in Donor-Recipient Richness as Determinants of Fecal Microbiota Transplantation Efficacy in Ulcerative ColitisECCO'25 Berlin
Year: 2025
Authors: Deleu, Sara
DOP021: Appendectomy regulates intestinal flora-bile acid axis inhibits macrophage lipid metabolism and improves Ulcerative ColitisECCO'25 Berlin
Year: 2025
Authors: Chu, Feifei
DOP022: Shared and Distinct Features of the Gut Microbiome in Immune-mediated Inflammatory Diseases: Initial Analysis from the INTEGRATE Cohort StudyECCO'25 Berlin
Year: 2025
Authors: Kim, Hyun Sik
DOP023: Bifidobacterium-candida warfare in the gut of patients with ulcerative colitisECCO'25 Berlin
Year: 2025
Authors: Jangi, Sushrut
DOP024: Transport of pks+ E. coli derived genotoxin colibactin from bacteria into host cellECCO'25 Berlin
Year: 2025
Authors: Schloderer, Johannes
DOP025: Subjects sharing bacterial amplicon sequence variants exhibit differences in their IgA and IgG coating of gut bacteria, with enrichment of IgG binding for bacteria typically found in the oral cavityECCO'25 Berlin
Year: 2025
Authors: Haberman Ziv, Yael